Elucidating Skeletal Muscle Novel Molecular Mechanisms of Type 2 Diabetes Mellitus - PROJECT SUMMARY More than 38 million Americans have diabetes, and about 90-95% of them have Type 2 diabetes mellitus (T2DM). T2DM affects muscles, typically in the lower extremities, by impairing blood flow. These changes are often gradual and subtle, and the onset of clinical symptoms and deficits may be difficult to recognize. Skeletal muscle insulin resistance and mitochondrial dysfunction are hallmarks of T2D. Both human and animal studies of T2DM demonstrated elevated intramyocellular lipids (IMCL) and association to IR. Some other important metabolites linked to T2DM are taurine (Tau; antioxidant/metabolism), carnosine (Car; pH regulation), acetylcarnitine (ALC; glucose homeostasis). However, studies investigating the role of these metabolites in glucose metabolism are limited and the precise mechanisms are unclear. As a complex metabolic disease, there is a need for novel non-invasive techniques to permit repeated assessments of these metabolites to facilitate development of new treatments that can effectively slow down the progression of T2DM while minimizing toxic side effects. In the proposed study, we will develop a metabolite cycled (MC) semi-laser localized 4D Echo Planar Total Correlated Spectroscopic Imaging (EP-TOCSI) sequence to examine skeletal muscle metabolites/lipids in a clinically feasible scan time. MC enables simultaneous water and metabolite acquisition without scan-time extension, minimizing magnetization transfer effects and improving metabolite and lipid quantification over conventional water-suppressed MRS. Thus, using 30 T2DM and 30 healthy controls, the specific aims are to 1) develop a novel metabolite cycled (MC) EP-TOCSI sequence and evaluate the stability, reliability, and accuracy in phantom and 10 healthy adults on a whole body 3T MRI/MRS scanner; (2) quantify upfield lipids/metabolites (IMCL/EMCL, unsaturation index, Tau, Cr, ALC, and Cho) and downfield metabolite (Car) in T2DM and controls; (3) evaluate relationships between altered lipid/metabolite levels, IMCL/EMCL unsaturation indices, serum biomarkers (fasting glucose, HbA1c), anthropometric measures, and insulin resistance (HOMA-IR, Matsuda index) in people withT2DM. In summary, by implementing an optimal version of water unsuppressed multi-voxel TOCSI, the objective is to examine different muscle groups including fast-twitch (tibialis anterior) and slow-twitch (soleus) for relayed cross peaks and downfiled/upfield metabolite/lipids in T2DM patients, and assess link between metabolites, lipids and clinical/physiological parameters. Successful completion of the projects will lead to technologies that contribute to improved understanding of not only T2DM but could also help with other conditions, especially those involving metabolic dysfunction. By confirming the reduction of taurine, carnosine, acetylcarnitine as seen in animal studies, it can pave the way for using these metabolites as therapeutic supplement against the development of T2DM and its complications, and could dramatically improve the morbidity, mortality, and life quality. Additionally, implementing this technique in other areas, like the brain, could uncover new pathways for neurological disorders and other health concerns.